XML 53 R37.htm IDEA: XBRL DOCUMENT
v3.25.4

Stockholders Equity (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2025
Stockholders Equity [Line Items] |
Schedule of Outstanding Warrants to Purchase Common Stock Issued to Stockholders | As of December 31, 2025, the Company had the following outstanding warrants to purchase Common Stock issued to stockholders:
Warrant |  | Issuance Date |  | Expiration Date |  | Exercise Price Per Share |  |  | Number of Shares of Common Stock Underlying Warrants |
2021 Registered Direct Offering Warrants |  | July 28, 2021 |  | January 28, 2027 |  |  | 950.00 |  |  |  | 14,808 |
Merger Warrants |  | March 15, 2024 |  | January 28, 2027 |  |  | 950.00 |  |  |  | 11,404 |
Private Placement Warrants |  | March 15, 2024 |  | July 9, 2026 |  |  | 43.91 |  |  |  | 203,444 |
Registered Pre-Funded Warrants |  | February 25, 2025 |  | April 21, 2030 |  |  | 0.0019 |  |  |  | 42,381 |
Private Pre-Funded Warrants |  | February 25, 2025 |  | April 21, 2030 |  |  | 0.0019 |  |  |  | 46,232 |
Common Warrants |  | February 25, 2025 |  | April 21, 2030 |  |  | 17.68 |  |  |  | 312,503 |
Inducement Warrants |  | February 25, 2025 |  | April 21, 2030 |  |  | 17.68 |  |  |  | 366,087 |
A&R Warrants |  | February 25, 2025 |  | April 21, 2030 |  |  | 0.0019 |  |  |  | 157,603 |
|  |  |  |  |  |  |  |  |  |  | 1,154,462 |
As of December 31, 2025, and 2024, the Company had the following outstanding compensation related warrants to purchase Common Stock as follows:
Warrant |  | Issuance Date |  | Expiration Date |  |  | Exercise Price Per Share |  |  | Number of Shares of Common Stock Underlying Warrants |
Private Warrants issued to scientific founders* |  | November 27, 2017 |  | - |  |  |  | - |  |  |  | 16 |
Landlord Warrants** |  | March 15, 2024 |  | January 28, 2027 |  |  |  | 950.00 |  |  |  | 1,316 |
Agents Warrants |  | March 15, 2024 |  | July 9, 2026 |  |  |  | 43.91 |  |  |  | 50,126 |
|  |  |  |  |  |  |  |  |  |  |  | 51,458 |
* | In November 2017, BiomX Israel issued 298 warrants to its founders. The warrants were fully vested at their grant date and will expire immediately prior to a consummation of an M&A transaction. The warrants did not expire as a result of the Recapitalization Transaction and have no exercise price. The Merger Agreement as described in note 1C does not apply for such M&A transaction as defined in the grant agreement.
** | See Note 5
Schedule of Fair Value of the Agents Warrants Using the Black-Scholes Model | The fair value of each option was estimated as of the date of grant using the Black-Scholes option-pricing model using the following assumptions:
|  | 2025 |  |  | 2024 |
Underlying value of Common Stock ($) |  |  | 10.22 |  |  |  | 68.97 |
Exercise price ($) |  |  | 10.22 |  |  |  | 68.97 |
Expected volatility (%) |  |  | 110.5 |  |  |  | 112.6 |
Expected terms of the option (years) |  |  | 6.11 |  |  |  | 6.11 |
Risk-free interest rate (%) |  |  | 4.12 |  |  |  | 4.14 |
Schedule of Options Granted to Purchase the Company’s Common Stock Under the Company’s Stock Option Plans | A summary of options granted to purchase the Company’s Common Stock under the Company’s stock option plans are as follows:
|  | For year ended December 31, 2025 |
|  | Number of Options |  |  | Weighted average exercise price |  |  | Aggregate intrinsic value |
Outstanding at the beginning of period |  |  | 105,525 |  |  | $ | 77.71 |  |  | $ | 15 |
Granted |  |  | 63,716 |  |  |  | 10.22 |  |  |  |  |
Forfeited |  |  | (15,085 | ) |  |  | 56.88 |  |  |  |  |
Expired |  |  | (3,051 | ) |  |  | 58.71 |  |  |  |  |
Exercised |  |  | (718 | ) |  | $ | 0.79 |  |  |  |  |
Outstanding at the end of period |  |  | 150,387 |  |  |  | 51.94 |  |  | $ | - |
Exercisable at end of period |  |  | 41,096 |  |  |  | 92.45 |  |  |  |  |
Weighted average remaining contractual life – years as of December 31, 2025 |  |  | 8.21 |  |  |  |  |  |  |  |  |
Schedule of Stock-Based Payment Expenses | The following table sets forth the total stock-based payment expenses resulting from options, RSUs and warrants granted, included in the consolidated statements of operations:
|  | Year ended December 31, |
|  | 2025 |  |  | 2024 |
Research and development expenses, net |  |  | 711 |  |  |  | 600 |
General and administrative |  |  | 1,380 |  |  |  | 1,248 |
|  |  | 2,091 |  |  |  | 1,848 |
Agents Warrants [Member] |
Stockholders Equity [Line Items] |
Schedule of Fair Value of the Agents Warrants Using the Black-Scholes Model | The Company determined the fair value of the Agents Warrants using the Black-Scholes model as of March 5, 2024. The main assumptions used are as follows:
Underlying value of Common Stock ($) |  |  | 43.91 |
Exercise price ($) |  |  | 43.91 |
Expected volatility (%) |  |  | 100.6 |
Expected terms (years) |  |  | 2.32 |
Risk-free interest rate (%) |  |  | 4.4 |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8A -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 480 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1 Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details
Name: | us-gaap_ClassOfStockLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=phge_AgentsWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |